• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

CERIVASTATIN Drug Record

  • Summary
  • Interactions
  • Claims
  • CERIVASTATIN chembl:CHEMBL1477

    Alternate Names:

    BAYCOL
    CERIVASTATIN
    LIPOBAY
    LIPOBAY®
    CERIVASTATIN ACID
    (3R,5S,6E)-7-(4-(4-FLUOROPHENYL)-5-(METHOXYMETHYL)-2,6-BIS(1-METHYLETHYL)-3-PYRIDINYL)-3,5-DIHYDROXY-6-HEPTENOIC ACID
    (3R,5S,6E)-7-(4-(P-FLUOROPHENYL)-2,6-DIISOPROPYL-5-(METHOXYMETHYL)-3-PYRIDYL)-3,5-DIHYDROXY-6-HEPTENOIC ACID
    BAYCOL®
    pubchem.compound:446156
    chembl:CHEMBL1477
    rxcui:596723
    chemidplus:145599-86-6
    drugbank:00439

    Drug Info:

    (0 More Sources)

    Publications:

    Kameyama Y et al., 2005, Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells., Pharmacogenet Genomics
    Marciante KD et al., 2011, Cerivastatin, genetic variants, and the risk of rhabdomyolysis., Pharmacogenet Genomics
    Shiomi et al., 1999, Effect of cerivastatin sodium, a new inhibitor of HMG-CoA reductase, on plasma lipid levels, progression of atherosclerosis, and the lesional composition in the plaques of WHHL rabbits., Br. J. Pharmacol.
    Blumenthal, 2000, Statins: effective antiatherosclerotic therapy., Am. Heart J.
    Denoyelle et al., 2001, Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study., Carcinogenesis
    Wong et al., 2001, Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin., Clin. Cancer Res.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Ganné et al., 2000, Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits urokinase/urokinase-receptor expression and MMP-9 secretion by peripheral blood monocytes--a possible protective mechanism against atherothrombosis., Thromb. Haemost.
    Staffa JA et al., 2002, Cerivastatin and reports of fatal rhabdomyolysis., N Engl J Med
    Ishikawa C et al., 2004, A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin., J Hum Genet
  • CERIVASTATIN   RYR2

    Interaction Score: 7.73

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21386754


    Sources:
    PharmGKB

  • CERIVASTATIN   HMGCR

    Interaction Score: 5.69

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    10193776 10740137 11470741 11448925 11752352 11057870


    Sources:
    TTD

  • CERIVASTATIN   CYP2C8

    Interaction Score: 1.85

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11844864 15365880


    Sources:
    PharmGKB

  • CERIVASTATIN   SLCO1B1

    Interaction Score: 0.59

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15970799


    Sources:
    PharmGKB

  • PharmGKB: cerivastatin

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Kameyama Y et al., 2005, Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells., Pharmacogenet Genomics
    Marciante KD et al., 2011, Cerivastatin, genetic variants, and the risk of rhabdomyolysis., Pharmacogenet Genomics
    Ishikawa C et al., 2004, A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin., J Hum Genet

  • TTD: Cerivastatin

    • Version: 2020.06.01

    Alternate Names:
    D03KIA TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1477

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21